India's Dr Reddy's Laboratories , one of country's largest generic drugmakers, said that it is open to expanding its manufacturing footprint in the key U.S. market as tariff threat looms.

Dr Reddy's Laboratories Ltd (NYSE:RDY) achieved record high revenue exceeding $3.8 billion and crossed the $1 billion threshold in EBITDA for the first time. The company reported a year-over-year ...